FLUOROURACILE TEVA 1000 mg/20 ml clinical trials

FFCD 1605- OPTIPRIME: A phase II study evaluating FOLFOX + panitumumab according to a ‘stop-and-go’ strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment, as the first line in patients with metastatic colorectal adenocarcinoma without a RAS mutation

This study is looking at a new way to treat bowel cancer that has spread. It combines existing medications, panitumumab and FOLFOX, using a 'stop-and-go' approach. The aim is to see how long the treatment keeps the cancer under control before it grows again, for patients without a specific gene change (RAS mutation).